Clovis Oncology Prices IPO

Boulder-based Clovis Oncology, the developer of anti-cancer drugs, has priced its IPO, saying Tuesday evening that it is offering up 10,000,000 shares of its common stock at $13.00 per share. Clovis will debut on the NASDAQ Global Select Market as CLVS this morning. Clovis priced at the lower end of its initial, $13.00 to $15.00 range. Clovis was venture backed by Domain Associates, New Enterprise Associates, Versant Ventures, Aberdare Ventures, and Abingworth Bioventures, along with Pfizer.